• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对于浸润性乳腺癌,谁仍然需要进行腋窝手术分期?

Who still needs surgical staging of the axilla for invasive breast cancer?

作者信息

Kelley Kathryn, Sener Stephen F

机构信息

University of Southern California-Hoag Memorial Hospital Presbyterian Breast Surgical Oncology Fellowship, Los Angeles, California, USA.

Los Angeles General Medical Center, Los Angeles, California, USA.

出版信息

J Surg Oncol. 2025 Jan;131(1):6-11. doi: 10.1002/jso.27753. Epub 2024 Jun 21.

DOI:10.1002/jso.27753
PMID:39031783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11874201/
Abstract

Sentinel lymphadenectomy may be safely omitted for postmenopausal patients with low-risk estrogen-receptor-positive cancers who have a negative pretreatment axillary ultrasound. Surgical staging should still be done for patients who are premenopausal or postmenopausal with high-risk estrogen receptor-positive cancers, for those having neoadjuvant chemotherapy, or those with estrogen-receptor-negative or human epidermal growth factor receptor-positive cancers.

摘要

对于绝经后、雌激素受体阳性、低风险且术前腋窝超声检查阴性的癌症患者,可安全地省略前哨淋巴结切除术。对于绝经前或绝经后、雌激素受体阳性、高风险癌症患者、接受新辅助化疗的患者或雌激素受体阴性或人表皮生长因子受体阳性癌症患者,仍应进行手术分期。

相似文献

1
Who still needs surgical staging of the axilla for invasive breast cancer?对于浸润性乳腺癌,谁仍然需要进行腋窝手术分期?
J Surg Oncol. 2025 Jan;131(1):6-11. doi: 10.1002/jso.27753. Epub 2024 Jun 21.
2
Use of ultrasound and MRI to stage the axilla for breast cancer before and after neoadjuvant chemotherapy prior to targeted sentinel lymphadenectomy.使用超声和 MRI 在新辅助化疗前和靶向前哨淋巴结活检前对乳腺癌进行腋窝分期。
Breast Cancer Res Treat. 2024 Aug;206(3):595-602. doi: 10.1007/s10549-024-07332-8. Epub 2024 May 3.
3
Validation of sentinel lymph node biopsy in breast cancer women N1-N2 with complete axillary response after neoadjuvant chemotherapy. Multicentre study in Tarragona.新辅助化疗后腋窝完全缓解的 N1 - N2 期乳腺癌女性前哨淋巴结活检的验证。塔拉戈纳的多中心研究。
Rev Esp Med Nucl Imagen Mol. 2016 Jul-Aug;35(4):221-5. doi: 10.1016/j.remn.2015.12.007. Epub 2016 Feb 2.
4
Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma.浸润性乳腺癌术前化疗后前哨淋巴结活检假阴性率增加。
Cancer. 2000 Dec 1;89(11):2187-94.
5
Management of the axilla in patients with breast cancer and positive sentinel lymph node biopsy: An evidence-based update in a European breast center.乳腺癌患者和前哨淋巴结活检阳性患者腋窝的处理:欧洲乳腺中心的循证更新。
Eur J Surg Oncol. 2020 Jan;46(1):15-23. doi: 10.1016/j.ejso.2019.08.013. Epub 2019 Aug 13.
6
Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.一步法核酸扩增(OSNA)术中前哨淋巴结活检可避免新辅助化疗治疗乳腺癌女性行腋窝淋巴结清扫术。
Eur J Surg Oncol. 2013 Aug;39(8):873-9. doi: 10.1016/j.ejso.2013.05.002. Epub 2013 May 25.
7
Management of axillary disease.腋窝疾病的管理
Surg Oncol Clin N Am. 2014 Jul;23(3):473-86. doi: 10.1016/j.soc.2014.03.007. Epub 2014 Apr 13.
8
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.初诊为经细胞学证实淋巴结阳性乳腺癌患者新辅助化疗后的前哨淋巴结活检
Clin Breast Cancer. 2016 Aug;16(4):299-304. doi: 10.1016/j.clbc.2016.02.009. Epub 2016 Feb 11.
9
Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node.前哨淋巴结清扫术对小叶组织学类型且前哨淋巴结阴性的乳腺癌患者腋窝的控制效果等同于腋窝淋巴结完全清扫术。
Am J Surg. 2005 Oct;190(4):598-601. doi: 10.1016/j.amjsurg.2005.06.021.
10
Improved axillary staging of breast cancer with sentinel lymphadenectomy.前哨淋巴结切除术改善乳腺癌腋窝分期
Ann Surg. 1995 Sep;222(3):394-9; discussion 399-401. doi: 10.1097/00000658-199509000-00016.

本文引用的文献

1
Use of ultrasound and MRI to stage the axilla for breast cancer before and after neoadjuvant chemotherapy prior to targeted sentinel lymphadenectomy.使用超声和 MRI 在新辅助化疗前和靶向前哨淋巴结活检前对乳腺癌进行腋窝分期。
Breast Cancer Res Treat. 2024 Aug;206(3):595-602. doi: 10.1007/s10549-024-07332-8. Epub 2024 May 3.
2
Ribociclib plus Endocrine Therapy in Early Breast Cancer.来曲唑联合内分泌治疗早期乳腺癌。
N Engl J Med. 2024 Mar 21;390(12):1080-1091. doi: 10.1056/NEJMoa2305488.
3
Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial.前哨淋巴结活检与阴性超声腋窝淋巴结结果的小乳腺癌患者不进行腋窝手术的比较:SOUND 随机临床试验。
JAMA Oncol. 2023 Nov 1;9(11):1557-1564. doi: 10.1001/jamaoncol.2023.3759.
4
Axillary lymph node recurrence following wire-directed sentinel lymph node dissection for breast cancer patients with biopsy-proven axillary metastases prior to neoadjuvant chemotherapy at a safety net medical center.在一家安全网医疗中心,对新辅助化疗前活检证实腋窝转移的乳腺癌患者进行导丝定向前哨淋巴结活检后,发生腋窝淋巴结复发。
J Surg Oncol. 2023 Jul;128(1):9-15. doi: 10.1002/jso.27241. Epub 2023 Mar 18.
5
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.阿贝西利联合内分泌治疗激素受体阳性、HER2 阴性、淋巴结阳性、高危早期乳腺癌(monarchE):一项随机、开放标签、III 期临床试验的预先计划的中期分析结果。
Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6.
6
Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.乳腺癌前哨淋巴结阳性后腋窝放疗或手术:EORTC 10981-22023 AMAROS 试验的 10 年随机对照结果。
J Clin Oncol. 2023 Apr 20;41(12):2159-2165. doi: 10.1200/JCO.22.01565. Epub 2022 Nov 16.
7
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.21 基因检测在淋巴结阳性乳腺癌中预测化疗获益。
N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1.
8
Diagnostic Performance of Noninvasive Imaging for Assessment of Axillary Response After Neoadjuvant Systemic Therapy in Clinically Node-positive Breast Cancer: A Systematic Review and Meta-analysis.临床淋巴结阳性乳腺癌新辅助全身治疗后腋窝反应的无创影像学评估的诊断性能:系统评价和荟萃分析。
Ann Surg. 2021 Apr 1;273(4):694-700. doi: 10.1097/SLA.0000000000004356.
9
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.瑞博西利联合氟维司群治疗晚期乳腺癌的总生存期。
N Engl J Med. 2020 Feb 6;382(6):514-524. doi: 10.1056/NEJMoa1911149. Epub 2019 Dec 11.
10
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.临床和基因组风险指导乳腺癌辅助治疗的应用。
N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.